Lupin gets USFDA nod for myelodysplastic syndrom drug

The company has received an approval from the United States Food and Drug Administration (USFDA) to market Decitabine for Injection, 50 mg/vial, single-dose vial, Lupin said in a statement.

Original source: https://health.economictimes.indiatimes.com/news/pharma/lupin-gets-usfda-nod-for-myelodysplastic-syndrom-drug/66634579?utm_source=RSS&utm_medium=ETRSS

Related Posts